Bausch Health Companies Inc. (BHC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 20/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.31% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
- Best Value Stocks to Buy for September 22nd
- Bausch Health (BHC) Expands Probiotic Skincare Bet To Six New Markets
- Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
- Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
- Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
- Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
- Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bausch Health Companies Inc..
Full BHC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.